This meta-analysis involved 1109 IDH-mutated AML patients from 3 RCTs [21, 23, 25] and 8 prospective cohort studies (7 articles) [14, 22, 24, 26–29], including 715 R/R AML patients with IDH mutations and 394 newly diagnosed AML patients with IDH mutations. This evidence concerns the gene IDH1 and acute myeloid leukemia.